Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

Antonio Cuneo; Monia Marchetti; Giovanni Barosi; Atto Billio; Maura Brugiatelli; Stefania Ciolli; Luca Laurenti; Francesca Romana Mauro; Stefano Molica; Marco Montillo; Pierluigi Zinzani; Sante Tura

doi:10.1016/j.leukres.2014.06.017

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

Antonio Cuneo, Monia Marchetti, Giovanni Barosi, Atto Billio, Maura Brugiatelli, Stefania Ciolli, Luca Laurenti, Francesca Romana Mauro, Stefano Molica, Marco Montillo, Pierluigi Zinzani, Sante Tura

Research output: Contribution to journal › Article

9 Citations (Scopus)

Abstract

By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.

Original language	English
Pages (from-to)	1269-1277
Number of pages	9
Journal	Leukemia Research
Volume	38
DOIs	https://doi.org/10.1016/j.leukres.2014.06.017
Publication status	Published - 2014

Keywords

Bendamustine
Chronic lymphocytic leukemia
First line treatment
Guidelines

Access to Document

10.1016/j.leukres.2014.06.017

Cite this

Cuneo, A., Marchetti, M., Barosi, G., Billio, A., Brugiatelli, M., Ciolli, S., Laurenti, L., Mauro, F. R., Molica, S., Montillo, M., Zinzani, P., & Tura, S. (2014). Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research, 38, 1269-1277. https://doi.org/10.1016/j.leukres.2014.06.017

@article{3ccfce0b9e20499f8b9106ba596cfec6,

title = "Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group",

abstract = "By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.",

keywords = "Bendamustine, Chronic lymphocytic leukemia, First line treatment, Guidelines, Bendamustine, Chronic lymphocytic leukemia, First line treatment, Guidelines",

author = "Antonio Cuneo and Monia Marchetti and Giovanni Barosi and Atto Billio and Maura Brugiatelli and Stefania Ciolli and Luca Laurenti and Mauro, {Francesca Romana} and Stefano Molica and Marco Montillo and Pierluigi Zinzani and Sante Tura",

year = "2014",

doi = "10.1016/j.leukres.2014.06.017",

language = "English",

volume = "38",

pages = "1269--1277",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Oxford,United Kingdom: Elsevier Science Limited -Oxford : Pergamon, 1977-",

}

Cuneo, A, Marchetti, M, Barosi, G, Billio, A, Brugiatelli, M, Ciolli, S, Laurenti, L, Mauro, FR, Molica, S, Montillo, M, Zinzani, P & Tura, S 2014, 'Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group', Leukemia Research, vol. 38, pp. 1269-1277. https://doi.org/10.1016/j.leukres.2014.06.017

TY - JOUR

T1 - Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

AU - Cuneo, Antonio

AU - Marchetti, Monia

AU - Barosi, Giovanni

AU - Billio, Atto

AU - Brugiatelli, Maura

AU - Ciolli, Stefania

AU - Laurenti, Luca

AU - Mauro, Francesca Romana

AU - Molica, Stefano

AU - Montillo, Marco

AU - Zinzani, Pierluigi

AU - Tura, Sante

PY - 2014

Y1 - 2014

N2 - By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.

AB - By using the GRADE system we produced the following recommendations for the use of bendamustine in the first-line treatment of CLL: (1) bendamustine with rituximab is recommended in elderly fit patients potentially eligible to FCR; (2) Bendamustine alone is recommended in patients who are candidate to chlorambucil alone; (3) Rituximab-bendamustine is recommended in patients not eligible to FCR, but suitable to receive rituximab. Consensus-based recommendations addressed evidence-orphan issues concerning the use of bendamustine in genetically-defined high-risk patients and the appropriate dose of bendamustine as single agent or in association with rituximab.

KW - Bendamustine

KW - Chronic lymphocytic leukemia

KW - First line treatment

KW - Guidelines

KW - Bendamustine

KW - Chronic lymphocytic leukemia

KW - First line treatment

KW - Guidelines

UR - http://hdl.handle.net/10807/63837

U2 - 10.1016/j.leukres.2014.06.017

DO - 10.1016/j.leukres.2014.06.017

M3 - Article

SN - 0145-2126

VL - 38

SP - 1269

EP - 1277

JO - Leukemia Research

JF - Leukemia Research

ER -

Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this